Honeywell International Inc. (HON) Stock Analysis
Is HON a good investment?
Honeywell International Inc. (HON) has a Plutrex AI rating of 70.0/100 as of August 21, 2026, indicating a Buy consensus. The stock is not classified as halal-compliant. Key strength: Best-in-class profitability: ROE 49.9% (82% above industry 27.48%), net margin 22.09% (108% above industry 10.64%), operating margin 20.25% (19% above industry 17.01%), gross margin 37.84% (34% above industry 28.24%) — durable competitive moat with no peer equivalent in the conglomerate sector. Main concern: PEG ratio of 5.81 remains critically elevated at 97% above the industry average of 2.95 — the 5-year EPS growth rate of only 3.76% (11.5% below industry 4.25%) cannot justify the current multiple on a growth-adjusted basis; the Chicago investor event headline 'Honeywell Slides 5% As Future Growth Guidance Disappoints' directly confirms the market's concern that long-term growth is structurally constrained.
Investment Summary
Honeywell (HON) at $218.32 is a high-quality industrial conglomerate that has pulled back 6.7% from $233.99 seven days ago, now trading meaningfully below the prior entry zone upper bound and approaching the lower bound of $225. The stock's investment case remains unchanged: exceptional profitability (ROE 49.9% vs. industry 27.5%, net margin 22.1% vs. industry 10.6%, operating margin 20.3% vs. industry 17.0%) coexists with a structurally constrained long-term growth outlook (5-year EPS growth 3.76% vs. industry 4.25%) and an elevated PEG ratio of 5.81 (97% above the industry average of 2.95). The P/E of 8.07x — a 57.8% discount to the industry average of 19.15x — is superficially attractive but reflects earnings quality concerns and the -34.3% YoY EPS decline. The analyst consensus target of $267.89 implies 22.7% upside from current levels, up from 14.6% upside at the prior report price of $233.99 — this is a materially improved risk/reward. News sentiment is positive at 75.4/100 with CFO commentary on strong July order trends, but the 'Honeywell Slides 5% As Future Growth Guidance Disappoints' headline from the Chicago investor event continues to weigh on sentiment and confirms the structural growth concern. The price decline to $218.32 now places HON squarely within an attractive entry zone for a partial position, improving the rating modestly to 70/100 and upgrading the recommendation to Buy from Hold.
Key Strengths
- Best-in-class profitability: ROE 49.9% (82% above industry 27.48%), net margin 22.09% (108% above industry 10.64%), operating margin 20.25% (19% above industry 17.01%), gross margin 37.84% (34% above industry 28.24%) — durable competitive moat with no peer equivalent in the conglomerate sector
- Near-term earnings acceleration: 20.1% next-year EPS growth (302% above industry 4.99%) supported by CFO commentary on strong July order trends and portfolio simplification; analyst consensus target of $267.89 implies 22.7% upside from $218.32 — materially improved from 14.6% upside at prior report price of $233.99
- Conservative balance sheet vs. peers: D/E of 1.46 is 39% below the industry average of 2.41, combined with $9.196B cash and $2.610B annual FCF; P/E of 8.07x (57.8% discount to industry 19.15x) provides a valuation floor and margin of safety relative to peers
Key Concerns
- PEG ratio of 5.81 remains critically elevated at 97% above the industry average of 2.95 — the 5-year EPS growth rate of only 3.76% (11.5% below industry 4.25%) cannot justify the current multiple on a growth-adjusted basis; the Chicago investor event headline 'Honeywell Slides 5% As Future Growth Guidance Disappoints' directly confirms the market's concern that long-term growth is structurally constrained
- Process Automation division weakness persists: headline 'HON's Process Automation Weakness Persists: What's Impeding Its Growth?' and 'Lower catalyst shipments are dragging down sales and margins in the division' signal a segment-level drag that could weigh on near-term execution; combined with the -34.3% YoY EPS decline and earnings quality concerns from the 263.9% earnings growth vs. -34.3% EPS disconnect, execution risk is non-trivial
Plutrex 10-Factor AI Breakdown
Fundamental Analysis
HON's fundamentals are bifurcated between exceptional profitability and mediocre growth. Profitability: Gross margin 37.84% (34% above industry 28.24%), operating margin 20.25% (19% above industry 17.01%), net margin 22.09% (108% above industry 10.64%), ROE 49.9% (82% above industry 27.48%) — HON is the undisputed profitability leader in the conglomerate sector. Financial Health: Cash of $9.196B and FCF of $2.610B annually are strong; D/E of 1.46 is elevated in absolute terms but 39% below the industry average of 2.41, making HON relatively conservative on leverage. Health score of 40/100 in Stage 1 was revised upward to 68/100 in industry context. Growth: 5-year EPS growth of 3.76% (11.5% below industry 4.25%) is the critical structural weakness — barely above inflation. Near-term EPS growth of 20.1% (302% above industry 4.99%) is a recovery catalyst, not a structural re-acceleration. Revenue growth of 4.3% is in-line with industry 4.41%. The disconnect between 263.9% earnings growth and -34.3% EPS YoY decline signals share count expansion or non-recurring items. Valuation: P/E of 8.07x (57.8% discount to industry 19.15x) appears cheap but is distorted by earnings quality issues. PEG of 5.81 (97% premium to industry 2.95) is the dominant valuation signal — the stock is expensive on a growth-adjusted basis. Analyst consensus target of $267.89 implies 22.7% upside from $218.32.
News Sentiment
Honeywell is navigating a pivotal moment as investors weigh a promising near-term recovery against lingering concerns about the industrial giant's long-term growth story. The stock has tumbled roughly 51.5% over six months — a stunning decline for a blue-chip conglomerate — and recently fell another 4.7% to $231.49 after a Chicago investor event where future growth guidance disappointed Wall Street expectations. That headline, 'Honeywell Slides 5% As Future Growth Guidance Disappoints,' crystallized what many investors already feared: that Honeywell's transformation into a leaner, more focused company may not translate into the accelerated growth they were hoping for. But there's a more optimistic chapter emerging. CFO Mike Stepniak reported strong July order trends following the company's ongoing portfolio transformation, suggesting the revenue pipeline is building momentum heading into the second half of 2026. And in a headline that caught bulls' attention — 'Honeywell Sees Strong Orders, Targets 15% EPS Growth in 2027' — management laid out an ambitious earnings target that, if achieved, would represent a meaningful re-acceleration from the current 3.76% five-year growth trajectory. The fly in the ointment? The Process Automation division continues to struggle, with lower catalyst shipments dragging down both sales and margins — a persistent weakness that the headline 'HON's Process Automation Weakness Persists' has kept front and center for investors. Leadership changes in Process Technology and related businesses signal management is aware of the problem, but execution remains the open question. For everyday investors, the story is this: Honeywell is a world-class business at a discounted price, but it needs to prove it can grow faster than inflation.
Risk Assessment
Primary risk: Structural growth constraint — 5-year EPS growth of 3.76% barely above inflation means the stock requires multiple expansion or a growth re-rating to generate meaningful long-term returns; if the 5-year growth rate deteriorates further, the PEG of 5.81 becomes even more problematic. Secondary risk: Process Automation division weakness ('HON's Process Automation Weakness Persists') and lower catalyst shipments dragging margins could disappoint near-term earnings, particularly given the -34.3% YoY EPS decline already in the data. Execution risk: The 20.1% near-term EPS growth recovery is the primary bull case catalyst — if this fails to materialize, the stock loses its key re-rating driver. Macro risk: D/E of 1.46, while below industry average, still represents meaningful leverage that amplifies downside in an economic slowdown. Mitigation: Entry at $213-$222 provides a 22.7% upside to analyst target with a stop at $202 (7.6% downside from entry midpoint of $217.50), yielding a 3.2x risk/reward ratio. Position sizing at 3.5% of portfolio reflects medium conviction — quality business with near-term catalyst but structural growth headwinds prevent higher conviction.
Related Halal Stocks
Related Stocks
Frequently Asked Questions
Is HON a halal stock?
No, Honeywell International Inc. (HON) is currently not classified as halal by AAOIFI criteria.
What is Plutrex's AI rating for HON?
Honeywell International Inc. (HON) has a Plutrex AI rating of 70.0/100 with a Buy consensus, based on a 10-factor analysis covering financial health, growth, valuation, profitability, debt, analyst sentiment, technical momentum, insider confidence, news sentiment, and halal compliance.
Is HON a good investment?
According to Plutrex AI, HON has a Buy rating (70.0/100). For the full analysis including trading plan and risk assessment, see the detailed breakdown above.
How can I invest in HON?
US stocks like HON can be bought through international brokers such as Interactive Brokers, accessible to Arab investors. Plutrex provides comprehensive analysis plus AI-generated trading plans with entry points, stop losses, and profit targets.
What are the main risks of investing in HON?
Plutrex AI identifies the main risks for HON by analyzing valuation, debt, market sentiment, and macro factors. See the Risk Assessment section above for the full breakdown.